APA (7th ed.) Citation

V, N., EM, H., TJ, J., JK, P., P, M., ME, S., . . . M, P. (2025). Preclinical concept studies showing advantage of an inhaled anti-CTGF/CCN2 protein for pulmonary fibrosis treatment. Nature communications, 16(1), 3251. https://doi.org/10.1038/s41467-025-58568-x

Chicago Style (17th ed.) Citation

V, Neiens, et al. "Preclinical Concept Studies Showing Advantage of an Inhaled Anti-CTGF/CCN2 Protein for Pulmonary Fibrosis Treatment." Nature Communications 16, no. 1 (2025): 3251. https://doi.org/10.1038/s41467-025-58568-x.

MLA (9th ed.) Citation

V, Neiens, et al. "Preclinical Concept Studies Showing Advantage of an Inhaled Anti-CTGF/CCN2 Protein for Pulmonary Fibrosis Treatment." Nature Communications, vol. 16, no. 1, 2025, p. 3251, https://doi.org/10.1038/s41467-025-58568-x.